Our findings that prolonged daily ATRi abolishes expansion of tumor-specific CD8+ T cells in the DLN and abolishes the survival benefits afforded by addition of short-course ATRi and sequential anti–PD-L1 treatment to RT show that ATRi must be ceased to allow a CD8+ T cell–dependent adaptive immune response. This evidence concerns the gene CD8A and neoplasm.